<DOC>
	<DOCNO>NCT02424682</DOCNO>
	<brief_summary>This study design evaluate safety tolerability Herceptin treatment patient human epidermal growth factor receptor 2 ( HER-2 ) positive metastatic breast cancer . Frequency , characteristic severity adverse event ( AE ) serious adverse event ( SAE ) follow evaluate safety Herceptin patient HER2 positive metastatic breast cancer .</brief_summary>
	<brief_title>Safety Herceptin/Trastuzumab Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed diagnosis metastatic breast cancer ( BC ) HER2neu overexpression Left Ventricular Ejection Fraction ( LVEF ) ECHO Multi Gated Acquisition Scan ( MUGA ) &gt; 50 % Good performance status : Eastern Cooperative Oncology Group ( ECOG ) scale &lt; = 2 life expectancy &gt; = 12 week Advanced pulmonary disease severe dyspnea Abnormal laboratory within 14 day prior registration Peripheral neuropathy &gt; grade 2 Presence central nervous system ( CNS ) metastasis Pregnancy lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>